Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 18:12:994155.
doi: 10.3389/fonc.2022.994155. eCollection 2022.

A spotlight on alkaloid nanoformulations for the treatment of lung cancer

Affiliations
Review

A spotlight on alkaloid nanoformulations for the treatment of lung cancer

Sindhoor S M et al. Front Oncol. .

Abstract

Numerous naturally available phytochemicals have potential anti-cancer activities due to their vast structural diversity. Alkaloids have been extensively used in cancer treatment, especially lung cancers, among the plant-based compounds. However, their utilization is limited by their poor solubility, low bioavailability, and inadequacies such as lack of specificity to cancer cells and indiscriminate distribution in the tissues. Incorporating the alkaloids into nanoformulations can overcome the said limitations paving the way for effective delivery of the alkaloids to the site of action in sufficient concentrations, which is crucial in tumor targeting. Our review attempts to assess whether alkaloid nanoformulation can be an effective tool in lung cancer therapy. The mechanism of action of each alkaloid having potential is explored in great detail in the review. In general, Alkaloids suppress oncogenesis by modulating several signaling pathways involved in multiplication, cell cycle, and metastasis, making them significant component of many clinical anti-cancerous agents. The review also explores the future prospects of alkaloid nanoformulation in lung cancer. So, in conclusion, alkaloid based nanoformulation will emerge as a potential gamechanger in treating lung cancer in the near future.

Keywords: alkaloids; drug resistance; lung cancer; nanoformulations; tumor targeting.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Mechanism of action of different alkaloids.
Figure 2
Figure 2
Nanoformulations of alkaloids in the management of lung cancer.
Figure 3
Figure 3
Number of publications [2002-2022] on basis of alkaloid application in treatment of cancers.
Figure 4
Figure 4
Number of publications [2002-2022] on basis of alkaloid application in treatment of lung cancers.

References

    1. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: New biological insights and recent therapeutic advances. CA. Cancer J Clin (2011) 61:91–112. doi: 10.3322/CAAC.20102 - DOI - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J Clin (2018) 68:394–424. doi: 10.3322/CAAC.21492 - DOI - PubMed
    1. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: Epidemiology, etiology, and prevention. Clin Chest Med (2011) 32:605–44. doi: 10.1016/J.CCM.2011.09.001 - DOI - PMC - PubMed
    1. Schabath MB, Cote ML. Cancer progress and priorities: Lung cancer. Cancer Epidemiol. Prev Biomarkers (2019) 28:1563–79. doi: 10.1158/1055-9965.EPI-19-0221 - DOI - PMC - PubMed
    1. Amararathna M, Goralski K, Hoskin DW, Rupasinghe HPV. Pulmonary nano-drug delivery systems for lung cancer: Current knowledge and prospects. J Lung Heal Dis (2019) 3:11–28.

LinkOut - more resources